CrystalGenomics Inc
KOSDAQ:083790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (33.8), the stock would be worth ₩-13 599.07 (1 181% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.1 | ₩1 258 |
0%
|
| Industry Average | 33.8 | ₩-13 599.07 |
-1 181%
|
| Country Average | 15.1 | ₩-6 062.88 |
-582%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
C
|
CrystalGenomics Inc
KOSDAQ:083790
|
96.7B KRW | -3.1 | -27.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 23.5 | 87.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 21.8 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 24.1 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 33.9 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 19.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 35.6 | 29.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.1 |
| Median | 15.1 |
| 70th Percentile | 28.4 |
| Max | 21 200 |
Other Multiples
CrystalGenomics Inc
Glance View
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.
